AdamsD, Gonzalez-DuarteA, O'RiordanWD, YangCC, UedaM, KristenAV, TournevI, SchmidtHH, CoelhoT, et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med, 379:11–21.
2.
HoySM. (2018). Patisiran: First Global Approval. Drugs, 78:1625–1631.
3.
NairJK, WilloughbyJL, ChanA, CharisseK, AlamMR, WangQ, HoekstraM, KandasamyP, Kel'inAV, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc, 136:16958–16961.
4.
SardhE, HarperP, BalwaniM, SteinP, ReesD, BissellDM, DesnickR, ParkerC, PhillipsJ, et al. (2019). Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med, 380:549–558.
5.
RayKK, StoekenbroekRM, KallendD, NishikidoT, LeiterLA, LandmesserU, WrightRS, WijngaardPLJ and KasteleinJJP. (2019). Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol [Epub ahead of print]; DOI: 10.1001/jamacardio.2019.3502.
6.
LindenD, AhnmarkA, PingitoreP, CiociolaE, AhlstedtI, AndreassonAC, SasidharanK, Madeyski-BengtsonK, ZurekM, et al. (2019). Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab, 22:49–61.
7.
RigoF, ChunSJ, NorrisDA, HungG, LeeS, MatsonJ, FeyRA, GausH, HuaY, et al. (2014). Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther, 350:46–55.
8.
FinkelRS, ChiribogaCA, VajsarJ, DayJW, MontesJ, De VivoDC, YamashitaM, RigoF, HungG, et al. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet, 388:3017–3026.
9.
TabriziSJ, LeavittBR, LandwehrmeyerGB, WildEJ, SaftC, BarkerRA, BlairNF, CraufurdD, PrillerJ, et al. (2019). Targeting Huntingtin expression in patients with Huntington's disease. N Engl J Med, 380:2307–2316.
10.
MillerTM, PestronkA, DavidW, RothsteinJ, SimpsonE, AppelSH, AndresPL, MahoneyK, AllredP, et al. (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol, 12:435–442.
11.
SpraggonL and CartegniL. (2013). Antisense modulation of RNA processing as a therapeutic approach in cancer therapy. Drug Discov Today Ther Strateg, 10:e139–e148.
12.
KimJ, HuC, Moufawad El AchkarC, BlackLE, DouvilleJ, LarsonA, PendergastMK, GoldkindSF, LeeEA, et al. (2019). Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Medicine, 381:1644–1652.
